Alantra Advises Perrigo on the Divestment of Richard Bittner to DCC Healthcare 

Apr 2025

Sell-side advisory

New York, London – Alantra acted as exclusive financial advisor to Perrigo Company plc on the divestment of Richard Bittner – a specialist CDMO of food supplements, medical devices, and pharmaceuticals based in Austria – as part of its manufacturing optimization program across the organization.  The business was sold to DCC Healthcare, strengthening their European presence and strategic positioning within the sector. 

Perrigo is a leading global consumer self-care company and a top 10 player in the European consumer health market. It is also the largest U.S. store brand provider of over-the-counter (OTC) medicines and infant formula. Perrigo owns well-known brands such as Opill, Compeed, Solpadeine, NiQuitin, and ACO. 

DCC is a leading international sales, marketing, and support services group operating across three key sectors: energy, healthcare, and technology. With a presence in 22 countries across four continents, DCC acquires, improves, and grows diverse businesses. Headquartered in Dublin, the company is listed on the London Stock Exchange and is a constituent of the FTSE 100.  

Alantra worked closely with multiple stakeholders at both Perrigo and Richard Bittner, providing strategic advice throughout the transaction, ensuring a seamless process for all parties involved.  

Rusty Ray, Managing Partner at Alantra, said: “This marks Alantra’s second transaction with both DCC and Perrigo and it is always a pleasure to work with the deal teams on both sides. It is a perfect example of our team’s expertise in Consumer Health across vertical value chain (from branded asset to manufacturing), as well as ability to collaborate and execute cross-border.” 

Charles Lanceley, Managing Director at Alantra, commented: “We are delighted to advise Perrigo on this transaction, and look forward to seeing Richard Bittner develop in the capable hands of DCC Healthcare’s management team. This is our 10th transaction in the global VMS CDMO space since 2021 – reinforcing our role as the #1 advisor in the sector.” 

This transaction underscores Alantra’s expertise in the consumer health sector, following recent advisory roles in branded asset transactions such as the sale of Windstar Medical to Merz, vH essentials to Wellspring, Viactiv to Kingdomway, Childs Farm to PZ Cussons, and Medik8 to Inflexion; it also reinforces Alantra’s market-leading position advising VMS CDMOs, having recently advised on the sale of UST to Somafina, Aakamp to Ourvita, Bee Health to INW, and the acquisition of Alphacaps by Armira.